Key points are not available for this paper at this time.
Standard treatment with neoadjuvant nivolumab plus chemotherapy significantly improves outcomes in patients with resectable non-small-cell lung cancer (NSCLC). Perioperative treatment (i.e., neoadjuvant therapy followed by surgery and adjuvant therapy) with nivolumab may further improve clinical outcomes.
Building similarity graph...
Analyzing shared references across papers
Loading...
Cascone et al. (Wed,) studied this question.
www.synapsesocial.com/papers/68e69d64b6db643587623078 — DOI: https://doi.org/10.1056/nejmoa2311926
Tina Cascone
Mark M. Awad
Jonathan Spicer
New England Journal of Medicine
Johns Hopkins University
Dana-Farber Cancer Institute
Chinese Academy of Medical Sciences & Peking Union Medical College
Building similarity graph...
Analyzing shared references across papers
Loading...